MYOS announces agreement with Cloud Pharmaceuticals MYOS announced that it has entered into a research and development agreement with Cloud Pharmaceuticals. The research and development program will focus on product candidates related to the inhibition of targets in the myostatin regulatory pathway as well as inflammatory mediators associated with sarcopenia and cachexia. Under the terms of the agreement MYOS will have proprietary rights to the design and structure of any small molecules developed for the muscle-health treatment market.
News For MYOS From The Last 14 Days
Check below for free stories on MYOS the last two weeks.
MYOS receives patent allowance in U.S. MYOS announced that it recently received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Serial No. 13/765,340 covering the Company's proprietary methods of manufacturing Fortetropin, the first clinically proven natural myostatin inhibitor. Upon issuance, the U.S. Patent entitled, "Process for Producing a Composition Containing Active Follistatin," will provide intellectual property protection for making the key ingredient in MYOS' core commercial muscle health products and carries a patent term through early 2033.